



An efficient process for the resolution of *cis*-4-*O*-protected-2-cyclopenten-1,4-diol using pancreatin lipase in $[C_8mim][PF_6]$ as a reusable system

Saibal Das^{a,b}, Srivari Chandrasekhar^b, Jhillu Singh Yadav^b, A. V. Rama Rao^c, René Grée^{a,*}

^a Université de Rennes 1, Laboratoire de Chimie et Photonique Moléculaires, CNRS UMR 6510, 35042 Rennes Cedex, France

^b Indian Institute of Chemical Technology, CSIR, Hyderabad 500 007, India

^c Avra Laboratories Pvt. Ltd, Hyderabad 501 507, India

ARTICLE INFO

Article history:

Received 20 October 2008

Accepted 12 November 2008

ABSTRACT

An efficient porcine pancreatin lipase-catalyzed transesterification of *cis*-4-*O*-TBS-2-cyclopenten-1,4-diol has been demonstrated in 1-octyl-3-methylimidazolium hexafluorophosphate, $[C_8mim][PF_6]$ ionic liquid, furnishing both the alcohol and the corresponding acetate in excellent enantiomeric purity and yields. This typical reaction system containing the suspension of enzymes in ionic liquid medium could be reused up to five times to prepare the required products in consistent yields and ee's. The corresponding optically active derivatives are very useful intermediates towards the synthesis of various types of compounds, including prostanoids.


© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Room temperature ionic liquids (RTILs) belong to a significant class of solvents, which has attracted growing interest over the last decade because of their unique physical, chemical and fine tuneable properties.¹ Since they can dissolve a large number of organic compounds as well as transition metal derivatives, as well as possess no effective vapour pressure and can be often recycled, RTILs offer an attractive alternative to conventional organic solvents.^{1,2} In recent years, they have also been demonstrated as very useful reaction media for bio-catalytic transformations and enzymatic resolutions.³ In particular, it has been established that enzymes

are stabilized in some RTILs, allowing the use of increased temperatures in specific reaction conditions and moreover, in combination with *scCO*₂ leading to novel and very efficient processes.⁴ In addition, specially designed Task Specific Ionic Liquids (TSILs) have recently been used for the enzymatic kinetic resolution of sec-alcohols.⁵

Optically active *cis*-2-cyclopenten-1,4-diol derivatives, and more specifically, the *O*-TBS compound **1**,⁶ are known to be very important intermediates towards the preparation of prostaglandins (PGs),⁷ carbocyclic nucleosides⁸ and other natural products.⁹ Furthermore, they have been used to prepare the corresponding enone **2**, which is another key intermediate in the synthesis of



Scheme 1. Access to (–)-*cis*-4-*O*-TBS-2-cyclopenten-1-ol, (–) **1**.

* Corresponding author. Tel.: +33 0 2 23 23 57 15; fax: +33 0 2 23 23 69 78.

E-mail address: rene.gree@univ-rennes1.fr (R. Grée).

various prostanoids and important biologically active molecules (Scheme 1).¹⁰ Therefore, improvements towards the synthesis and resolution of (\pm)-**1** and its analogues are always a subject of interest to fulfil with regard to the ongoing requirement towards the corresponding syntheses.

As part of our research programme on new developments towards the total synthesis of prostaglandins^{7b} (PGs), and based on our previous interest and results obtained in the use of RTILs,¹¹ we became involved in the development of new and efficient methods for the resolution of compound (\pm)-**1**. Herein, we report that the ionic liquid, [C₈mim][PF₆], can be used as a solvent medium to perform a very efficient resolution of (\pm)-**1** using Pancreatin Lipase, with significant advantages concerning the reaction conditions used, the purification procedure, and the reutilizations of the suspended enzyme in ionic liquid reaction mixture.¹²

2. Results and discussion

We have selected the ionic liquid, [C₈mim][PF₆], as the solvent medium, based on its physical properties:¹³ due to the long aliphatic C₈ chain, it has a low viscosity, density and melting point and should allow its use in a wide range of temperatures for certain reactions. Moreover, it also has low miscibility with water, which should minimize its loss during the extraction and washing procedures. Furthermore, it is also known that enzymes are usually active in RTILs containing the PF₆ anion, contrary to certain other counter anions.¹⁴

The resolution of *cis*-(\pm)-4-*O*-TBS-2-cyclopentene-1-ol (\pm)-**1** was performed using porcine pancreatin lipase in the ionic liquid [C₈mim][PF₆] under the required reaction parameters, based on the literature data,⁶ as indicated in Scheme 2. After optimization of the reaction conditions, (–)-*cis*-4-*O*-TBS-2-cyclopentene-1-ol (–)-**1** was obtained along with its corresponding acetate derivative (+)-*cis*-4-*O*-TBS-2-cyclopentenyl acetate (+)-**3** in 49.9% and 49.8% isolated yields, respectively, after ether extraction followed by chromatography on SiO₂.

The HPLC analysis was performed using Chiralcel OD column (iPrOH/hex = 1:99, 1 ml/min) indicating that the mono-protected diol (–)-**1** (detected at 199.9 nm) was obtained in >99% ee. On the other hand, the acetate derivative (+)-**3** (detected at 201.1 nm) was obtained in >96% ee.¹⁵

The above-mentioned resolution process using the porcine pancreatin lipase in the ionic liquid [C₈mim][PF₆] worked out to be a very efficient system for our purpose. It was observed that, after the extraction of the desired products, the enzyme was retained back in the ionic liquid medium as a uniform suspension. Therefore, it became of interest to check the possibility of reusing this particular homogeneous system for further runs. After drying this suspension under high vacuum (0.1 mmHg) for 5 h at 30 °C, it was subjected again to the resolution process on the same scale as for the first run by the addition of (\pm)-**1** and the other required reagents.

As indicated in Table 1, five runs could be successfully performed using the same reaction mixture containing porcine

Table 1

Recycling and reuse of the porcine pancreatin lipase in [C₈mim][PF₆]

Runs	Enantiomerically pure alcohol (–)- 1		Acetate derivative (+)- 3	
	ee's ^a (%)	Yield ^b (%)	ee's ^a (%)	Yield ^b (%)
1	>99	49.9	>96	49.8
2	>99	46.2	>96	48.8
3	>99	43.2	>96	47.6
4	>98	42.4	>96	47.6
5	>98	42.0	>96	46.8

^a Obtained using HPLC analysis using Chiral OD column.

^b Isolated yield after chromatography on SiO₂.

pancreatin lipase in [C₈mim][PF₆]. It was observed that each run gave excellent to good yields and ee's for the desired products. This result demonstrates that the enzyme porcine pancreatin lipase remains stable in ionic liquid [C₈mim][PF₆] even after 5 runs, showing no major loss in its activity and adding worth to our process for resolution. Extension of this methodology to other sec-alcohols is currently under active study in our groups.

3. Conclusion


In conclusion, we have demonstrated the first lipase-catalyzed enantioselective transesterification of *cis*-4-*O*-TBS-2-cyclopenten-1,4-diol in an ionic liquid as solvent medium to obtain enantiomerically pure compound in excellent ee's. Furthermore, the porcine pancreatin lipase was found to be stable and active in ionic liquid [C₈mim][PF₆]; the system containing enzyme and ionic liquid could be recycled and reused efficiently for further runs.

Acknowledgements

We thank CEFIPRA/IFCPAR for the financial support to this research (Project No. 7106).

References

- (a), 2nd ed. *Ionic Liquids in Synthesis*; Wasserscheid, P., Welton, T., Eds.; Wiley: VCH, Germany, 2008; vol. 1, (b) Wasserscheid, P.; Welton, T. *Ionic Liquids in Synthesis*; Wiley-VCH: Germany, 2003.
- Recent reviews on the use of ionic liquids in synthesis: (a) Jain, N.; Kumar, A.; Chauhan, S.; Chauhan, S. M. S. *Tetrahedron* **2005**, *61*, 1015–1060; (b) L  v  que, J.-M.; Luche, J.-L.; P  trier, C.; Roux, R.; Bonrath, W. *Green Chem.* **2002**, *4*, 357–360; (c) Dupont, J.; de Souza, R. F.; Suarez, P. A. Z. *Chem. Rev.* **2002**, *102*, 3667–3692; (d) Sheldon, R. *Chem. Commun.* **2001**, 2399–2407; (e) Seddon, M. J.; Earle, K. R. *Pure Appl. Chem.* **2000**, *72*, 1391–1398; (f) Wasserscheid, P.; Keim, W. *Angew. Chem., Int. Ed.* **2000**, *39*, 3772–3789; (g) Welton, T. *Chem. Rev.* **1999**, *99*, 2071–2084.
- For a recent review article see: van Rantwijk, F.; Sheldon, R. A. *Chem. Rev.* **2007**, *107*, 2755–2785, and references cited therein.
- See for instance: Lozano, P.; de Diego, T.; Carri  , D.; Vaultier, M.; Iborra, J. L. *Chem. Commun.* **2002**, 692.
- (a) Vaultier, M.; Kirschning, A.; Singh, V. *Ionic Liquids in Synthesis*, 2nd ed.; Wasserscheid, P., Welton, T., Eds.; Wiley: VCH, Germany, 2008; vol. 2, pp 488–527.; (b) Lourenco, N. M. T.; Afonso, C. A. M. *Angew. Chem., Int. Ed.* **2007**, *46*, 8178–8181.
- For previous in-depth studies on the synthesis and resolution of this compound see: Curran, T. T.; Hay, D. A.; Koegel, C. P. *Tetrahedron* **1997**, *53*, 1983–2004.
- (a) Collins, P. W.; Djuric, S. W. *Chem. Rev.* **1993**, *93*, 1533–1564; (b) Das, S.; Chandrasekhar, S.; Yadav, J. S.; Gr  e, R. *Chem. Rev.* **2007**, *107*, 3286–3337.
- (a) Watson, T. J. N.; Curran, T. T.; Hay, D. A.; Shah, R. S.; Wenstrup, D. L.; Webster, M. E. *Org. Process Res. Dev.* **1998**, *2*, 357–365; (b) Seley, K. L.; Schneller, S. W.; DeClercq, E. J. *Org. Chem.* **1997**, *62*, 5645–5646.
- Mulzer, J.; Giester, G.; Gilbert, M. *Helv. Chim. Acta* **2005**, *88*, 1560–1579.
- (a) Myers, A. G.; Hammond, M.; Wu, Y. *Tetrahedron Lett.* **1996**, *37*, 3083–3086; (b) Roy, A.; Schneller, S. W. *J. Org. Chem.* **2003**, *68*, 9269–9273.
- (a) Das, S.; Chandrasekhar, S.; Yadav, J. S.; Gr  e, R. *Tetrahedron Lett.* **2007**, *48*, 5305–5307; (b) Ansari, I. A.; Joyasawal, S.; Gupta, M. K.; Yadav, J. S.; Gr  e, R. *Tetrahedron Lett.* **2005**, *46*, 7507–7510; (c) Anjaiah, S.; Chandrasekhar, S.; Gr  e, R. *Adv. Synth. Catal.* **2004**, *346*, 1329–1334; (d) Anjaiah, S.; Chandrasekhar, S.; Gr  e, R. *J. Mol. Catal. A* **2004**, *214*, 133–136; (e) Anjaiah, S.; Chandrasekhar, S.; Gr  e, R. *Tetrahedron Lett.* **2004**, *45*, 569–571.



Scheme 2. Resolution of (\pm)-**1** using pancreatin lipase in [C₈mim][PF₆].

12. Grée, R.; Das, S.; Yadav, J. S.; Chandrasekar, S.; Pabbaraja, S.; RamaRao, A. V. Indian Patent No. 1530/CHE/2007.
13. Maruyama, T.; Yamamura, H.; Kotani, T.; Kamiya, N.; Goto, M. *Org. Biomol. Chem.* **2004**, 2, 1239–1244.
14. Kaar, J. L.; Jesionomski, A. M.; Berberich, J. A.; Moulton, R.; Russell, A. J. *J. Am. Chem. Soc.* **2003**, 125, 4125–4131.
15. *Typical experimental procedure: Resolution of cis-(±)-4-O-TBS-2-cyclopentene-1-ol*: The mono-protected alcohol, *cis*-(±)-4-O-TBS-2-cyclopentene-1-ol (2.6 g, 12.1 mmol), was dissolved in 5 ml of the ionic liquid [C₈mim(PF₆)] (which was dried before use for 24 h under high vacuum at 50 °C). Freshly distilled triethylamine (Et₃N) (1.18 ml, 8.5 mmol) was added and the reaction mixture was stirred for 30 min at room temperature under an argon atmosphere. Pancreatin Lipase from Sigma Aldrich (7.8 g, 3 wt equiv) was then added under an argon atmosphere and stirred for another 15 min followed by the addition of freshly distilled vinyl acetate (5.6 ml, 60.6 mmol) after which it was stirred for another 24 h under the same inert reaction condition. The extraction was carried out using 5 ml of dry diethyl ether (10 times) under an inert atmosphere. The combined organic layer was filtered through a pad of Celite, and then concentrated. A dense colourless liquid was obtained. Purification was done over silica gel using an eluent as the gradient system starting from 10% to 25% of ethyl acetate in pentane. The required *cis*-(–)-4-O-TBS-2-cyclopentene-1-ol (–)-**1** (*R*_f: 0.55, 20% ethyl acetate/pentane), 1.3 g and *cis*-(+)-4-O-TBS-2-cyclopentenyl acetate (+)-**3**; (*R*_f: 0.85, 20% ethyl acetate/pentane), 1.55 g were obtained in 49.9% and 49.8% yields, respectively. After drying for 5 h at 30 °C under high vacuum (0.1 mmHg), the suspension of lipase in ionic liquid was reused for the next runs.
Data for compound (–)-1: ¹H NMR (300 MHz, CDCl₃): δ 5.85 (dt, 1H, *J* = 5.6, 1.2 Hz), 5.74 (dt, 1H, *J* = 5.5, 1.3 Hz), 4.57 (t, 1H, 6.0 Hz), 4.50 (t, 1H, *J* = 6.0 Hz), 2.59 (dt, 1H, *J* = 13.8, 7.0 Hz), 1.78 (br s, 1H, OH), 1.52 (dt, 1H, *J* = 13.7, 4.4 Hz), 0.81 (s, 9H), 0.00 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 136.9, 135.6, 75.2, 75.1, 44.6, 25.8, 18.1, –4.6. HPLC analysis: Column Chiralcel OD column, *i*PrOH/hex = 1:99, 1 ml/min, UV detection at 199.9 nm, *R*_t = 6.3 min for (–)-**1**. [α]_D²¹ = –21.7 (c 1.6, CHCl₃). {Literature value; [α]_D²⁰ = –21.2 (c 0.89, CHCl₃); Cpd (–) 10 of Ref. 6}.
Data for compound (+)-3: ¹H NMR (300 MHz, CDCl₃): δ 5.89 (dt, 1H, *J* = 5.6, 1.5 Hz), 5.80 (dt, 1H, *J* = 5.5, 1.5 Hz), 5.37 (t, 1H, 6.0 Hz), 4.63 (t, 1H, *J* = 6.0 Hz), 2.72 (dt, 1H, *J* = 13.8, 7.3 Hz), 1.96 (s, 3H), 1.52 (dt, 1H, *J* = 13.8, 5.1), 0.81 (s, 9H), 0.00 (d, 6H, *J* = 1.7 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 170.8, 138.8, 131.1, 76.9, 74.8, 41.1, 25.8, 21.1, 18.1, –4.6 (d, *J* = 3.7 Hz). HPLC analysis: Column Chiralcel OD column, *i*PrOH/hex = 1:99, 0.8 ml/min, UV detection at 201.1 nm, *R*_t = 5.9 min for (+)-**3**. [α]_D²¹ = +0.3 (c 1.4, CHCl₃). {Literature value; [α]_D²⁰ = +0.4 (c 1, CHCl₃); Cpd (+)-**27** within Ref. 6}.